Search results for "Axis"

showing 10 items of 751 documents

An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development.

2010

Abstract Fetal trophoblast cells invading the decidua in the early phase of pregnancy establish complex interaction with the maternal extracellular matrix. We discovered that C1q was widely distributed in human decidual stroma in the absence of C4 and C3 and was actively synthesized by migrating extravillous trophoblasts. The cells expressed the messages for the three chains of C1q and secreted this complement component that interacted with the proteins of the decidual extracellular matrix. Solid phase-bound C1q promoted trophoblast adhesion and migration, and cell binding to C1q resulted in activation of ERK1/2 MAPKs. Ab inhibition experiments showed that the receptors for the globular hea…

medicine.medical_specialtyImmunologyCellIntegrinImmunoblottingchemical and pharmacologic phenomenaBiologyExtracellular matrixMicePre-Eclampsiaimmune system diseasesPregnancyInternal medicinemedicineCell AdhesionImmunology and AllergyAnimalsHumansImmunoprecipitationskin and connective tissue diseasesReceptorCell adhesionreproductive and urinary physiologyMicroscopy ConfocalC1q placental development.Reverse Transcriptase Polymerase Chain ReactionComplement C1qDeciduaTrophoblastPlacentationImmunohistochemistryPlacentationCell biologyTrophoblastsMice Inbred C57BLChemotaxis Leukocytemedicine.anatomical_structureEndocrinologyembryonic structuresbiology.proteinFemaleJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Safety and tolerability of omalizumab

2009

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody with proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post-marketing safety data. Analysis focuses on the risk of immune-system effects, hypersensitivity reactions, malignant neoplasia, parasitic in…

medicine.medical_specialtyImmunologyOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal HumanizedInfectionsImmunoglobulin EAnti-asthmatic AgentNeoplasmsInternal medicinemedicineHumansImmunology and AllergyAnti-Asthmatic AgentsAnaphylaxisAsthmaClinical Trials as Topicbiologybusiness.industryIncidence (epidemiology)Antibodies Monoclonalmedicine.diseaseThrombocytopeniaAsthmaAntibodies Anti-IdiotypicClinical trialTolerabilityImmunologybiology.proteinbusinessAnaphylaxismedicine.drugClinical & Experimental Allergy
researchProduct

Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism

2007

Acetylcholine may play a role in cell activation and airway inflammation. We evaluated the levels of both mRNA and protein of muscarinic M(1), M(2), M(3) receptors in human bronchial epithelial cell line (16HBE). 16HBE cells were also stimulated with acetylcholine and extracellular signal-regulated kinase1/2 (ERK1/2) and NFkB pathway activation as well as the IL-8 release was assessed in the presence or absence of the inhibitor of Protein-kinase (PKC) (GF109203X), of the inhibitor of mitogenic activated protein-kinase kinase (MAPKK) (PDO9805), of the inhibitor of kinaseB-alpha phosphorilation (pIkBalpha) (BAY11-7082), and of muscarinic receptor antagonists tiotropium bromide, 4-Diphenylacet…

medicine.medical_specialtyIndolesNeutrophilsScopolamine DerivativesBronchiMuscarinic AntagonistsBiologyPharmacologyMaleimideschemistry.chemical_compoundPiperidinesInternal medicineNitrilesMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptormedicineHumansRNA MessengerSulfonesTiotropium BromideProtein Kinase CCell Line TransformedAcetylcholine receptorFlavonoidsMitogen-Activated Protein Kinase 1PharmacologyMitogen-Activated Protein Kinase 3Gallamine TriethiodideInterleukin-8NF-kappa BMuscarinic acetylcholine receptor M3Epithelial CellsMuscarinic acetylcholine receptor M2PirenzepineMuscarinic acetylcholine receptor M1Receptors MuscarinicAcetylcholineChemotaxis LeukocyteEndocrinologychemistryTelenzepineAcetylcholinemedicine.drugEuropean Journal of Pharmacology
researchProduct

Leukocyte chemotactic activity in cultures of unstimulated human lymphocytes.

2009

We have shown earlier that unstimulated human lymphocytes in in vitro cultures produce migration inhibitory factor into the supernatant. The evidence of spontaneous lymphokine synthesis is strengthened further by this study, which demonstrates leukocyte chemotactic activity in these culture supernatants. The factor has a molecular weight of more than 5000 daltons, it resisted heating for 15 min at 100 degrees C, and showed maximum activity at dilution 1:4-1:8 of the supernatants.

medicine.medical_specialtyLymphokinesHot TemperatureChemistryLymphokineChemotaxisGeneral MedicineMolecular biologyIn vitroMonocytesMigration Inhibitory FactorMolecular WeightChemotaxis LeukocyteEndocrinologyInternal medicinemedicineHumansCell culture supernatantLymphocytesCells CulturedActa pathologica et microbiologica Scandinavica. Section C, Immunology
researchProduct

Incidence of infective endocarditis before and after the guideline modification regarding a more restrictive use of prophylactic antibiotics therapy …

2019

Infective endocarditis (IE) is a potentially life-threatening disease. Regardless the improvements in IE management, it remains associated with high mortality and severe complications. Staphylococci and streptococci account for 80% of all IE cases. Prevention of IE by appropriate administration of antibiotics before procedures with potential bacteremia in selected patients is recommended according to recent and current guidelines. However, recent studies, have questioned the efficacy of antimicrobial prophylaxis in special situations and in some patient-groups. As a consequence, the guideline of the French working group on IE in 2002, the American Heart Association (AHA) guideline in 2007, …

medicine.medical_specialtyMEDLINENiceDisease030204 cardiovascular system & hematology03 medical and health sciencesPostoperative Complications0302 clinical medicinemedicineHumans030212 general & internal medicineAntibiotic prophylaxisIntensive care medicinecomputer.programming_languageEndocarditisbusiness.industryIncidenceIncidence (epidemiology)GuidelineAntibiotic Prophylaxismedicine.diseaseUnited StatesEuropeInfective endocarditisBacteremiaGuideline AdherenceCardiology and Cardiovascular MedicinebusinesscomputerMinerva Cardioangiologica
researchProduct

Sodium thiosulfate not always resolves calciphylaxis: an ambiguous response

2011

Calciphylaxis is a severe “vascular ossification–calcification,” associated with a very high mortality rate that involvesarterial wall, venular wall, and nerves resulting in ischemia and necrosis of skin, subcutaneous fat, visceral organs,and skeletal muscles. Sodium thiosulfate has recently been used as a novel treatment option for calciphylaxisbecause of its dual role as an antioxidant and a chelator. Multiple case reports demonstrated that such therapy hasresulted in pain relief and healing of skin ulceration. We report a case of calciphylaxis of large severity that had anambiguous response to sodium thiosulfate treatment (improvement of symptomatology and skin lesions, improve-ment of b…

medicine.medical_specialtyNecrosisSettore MED/09 - Medicina InternaIschemiaThiosulfatesSodium thiosulfateCritical Care and Intensive Care MedicineGastroenterologySubcutaneous fatSeverity of Illness IndexAntioxidantschemistry.chemical_compoundFatal OutcomeInternal medicineSeverity of illnessmedicineHumansChelating AgentsThiosulfateCalciphylaxisbusiness.industryCalciphylaxisGeneral MedicineMiddle Agedmedicine.diseasethiosulfate calciphylaxisSurgeryTreatment OutcomechemistryNephrologyFemalemedicine.symptombusinessBlood parameters
researchProduct

Antimicrobial therapy in neonatal intensive care unit

2015

Severe infections represent the main cause of neonatal mortality accounting for more than one million neonatal deaths worldwide every year. Antibiotics are the most commonly prescribed medications in neonatal intensive care units (NICUs) and in industrialized countries about 1% of neonates are exposed to antibiotic therapy. Sepsis has often nonspecific signs and symptoms and empiric antimicrobial therapy is promptly initiated in high risk of sepsis or symptomatic infants. However continued use of empiric broad-spectrum antibiotic treatment in the setting of negative cultures especially in preterm infants may not be harmless. The benefits of antibiotic therapy when indicated are clearly enor…

medicine.medical_specialtyNeonatal intensive care unitmedicine.drug_classAntibioticsReviewGlobal HealthInfant Newborn DiseasesSepsisIntensive Care Units NeonatalIntensive caremedicineHumansAntibiotic prophylaxisAdverse effectIntensive care medicineEmpiric therapyAntibiotic stewardshipNeonatal sepsisbusiness.industryInfant NewbornAntibioticAntibiotic ProphylaxisNewbornmedicine.diseaseAnti-Bacterial AgentsAntibiotic; Antibiotic stewardship; Empiric therapy; Neonatal sepsis; Newborn; Resistant bacteria; Pediatrics Perinatology and Child HealthPediatrics Perinatology and Child HealthNeonatal sepsisNeonatal sepsiResistant bacteriabusinessEmpiric therapyItalian Journal of Pediatrics
researchProduct

Causality-based diagnosis of histamine-related cardiorespiratory disturbances in surgical patients

1998

medicine.medical_specialtyNeurologyImmunologyPharmacology toxicologyHistamine ReleaseSkin Diseaseschemistry.chemical_compoundDouble-Blind MethodTachycardiaInternal medicineBradycardiamedicineHumansIntensive care medicineAnaphylaxisPharmacologybusiness.industryCardiorespiratory fitnessCausalityRheumatologyHistamine H2 AntagonistschemistryHypertensionHistamine H1 AntagonistsHypotensionbusinessHistamineHistamineSurgical patientsInflammation Research
researchProduct

Oral hygiene instructions and professional control as part of the treatment of desquamative gingivitis. Systematic review

2019

Background The aim of this present article was to evaluate the scientific evidence on the efficacy of daily hygiene and professional prophylaxis for treatment of desquamative gingivitis. Material and Methods The present systematic review was conducted following the PRISMA protocol. Searches were carried out in Pubmed, Embase, Web of Science and Cochrane Library up to July 2018, randomized clinical trials and cohort studies on desquamative gingivitis (DG), and oral diseases joined to DG. Results After screening, we found that nine publications met the eligibility criteria eight cohort studies and one randomized control trial. The diagnosis of the diseases corresponded to oral lichen planus (…

medicine.medical_specialtyPemphigoidDatabases FactualBiopsyPemphigoid Benign Mucous MembraneDental PlaqueReviewCochrane LibraryOral hygienelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansGeneral DentistryOral Medicine and Pathologyintegumentary systembusiness.industryDental Plaque IndexDental Prophylaxis030206 dentistryOral Hygiene:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseGingivitisDental PolishingDesquamative gingivitisstomatognathic diseasesOtorhinolaryngologyMeta-analysisUNESCO::CIENCIAS MÉDICASDental ScalingSurgeryOral lichen planusPeriodontal IndexbusinessPemphigusLichen Planus OralCohort study
researchProduct

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic ha…

2021

BACKGROUND: Cytomegalovirus (CMV) is a complication of allogeneic haematopoietic cell transplantation (allo-HCT). ASP0113, a DNA-based vaccine, contains two plasmids encoding human CMV glycoprotein B and phosphoprotein 65 (pp65). We assessed ASP0113 in CMV-seropositive allo-HCT recipients. METHODS: In this phase 3, randomised, placebo-controlled study, CMV-seropositive allo-HCT recipients were randomly assigned (1:1) via interactive response technology to receive five injections of 1 mL of 5 mg/mL ASP0113 or placebo. The pharmacist and designated staff were unblinded. Masked syringes maintained the blind for patients and study personnel. Efficacy and safety analyses included patients who re…

medicine.medical_specialtyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerDiseaseGANCICLOVIRPlacebo01 natural sciencesPROPHYLAXIS03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMedicine General & Internal[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneral & Internal MedicinemedicineCYTOMEGALOVIRUS DISEASE030212 general & internal medicine0101 mathematicsAdverse effectlcsh:R5-920Science & Technologybusiness.industryIncidence (epidemiology)010102 general mathematicsGeneral MedicineOdds ratioConfidence interval3. Good healthbusinessComplicationlcsh:Medicine (General)Life Sciences & BiomedicineResearch PaperEClinicalMedicine
researchProduct